Tier 4 — mechanistic

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation in Hospitalized Adults

Paschalis Vergidis, James L. Kirkland
ClinicalTrials.gov trial registry record 2020

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: Mayo Clinic.
Competing interests
Registry record; no results manuscript is available for a manuscript-level conflict-of-interest statement.

Study snapshot

DesignPhase 2 randomized double-blind placebo-controlled parallel trial.
ModelHospitalized adults aged 18 years and older with SARS-CoV-2 infection.
SampleTarget enrollment: 80 participants.
InterventionFisetin approximately 20 mg/kg/day orally or by enteral tube for two consecutive days versus placebo.
DurationTwo-day treatment course with inpatient clinical follow-up; registry listed primary/study completion around September 2026.
EndpointsOxygenation status; Progression to supplemental oxygen or assisted ventilation; COVID-19 disease severity; Inflammatory outcomes; Physical function/frailty; Safety and tolerability

What the study showed, in plain terms

COVID-FISETIN is a Mayo Clinic Phase 2 placebo-controlled study of a two-day fisetin course in hospitalized adults with COVID-19. The trial asks whether fisetin can reduce deterioration in oxygenation, hyperinflammation and disease progression.

As of September 2026, the registry still lists the study as active but not recruiting and no results are posted. The estimated completion date has arrived, but estimated completion is not the same as published outcomes.

Key findings

  • Target enrollment is 80 hospitalized adults.
  • The registered fisetin regimen is approximately 20 mg/kg/day for two consecutive days.
  • No outcome results were posted at the September 2026 check.

What this study can and cannot tell us

  • No results available.
  • Acute hospitalized COVID-19 is a disease-specific context and cannot answer general longevity questions.
  • Estimated completion dates do not establish that the study has completed or that results exist.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology